Sartorius Stedim Biotech SA (DIM) - Net Assets
Based on the latest financial reports, Sartorius Stedim Biotech SA (DIM) has net assets worth €4.07 Billion EUR as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.88 Billion) and total liabilities (€3.81 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.07 Billion |
| % of Total Assets | 51.68% |
| Annual Growth Rate | 18.97% |
| 5-Year Change | 171.34% |
| 10-Year Change | 521.71% |
| Growth Volatility | 25.65 |
Sartorius Stedim Biotech SA - Net Assets Trend (2005–2024)
This chart illustrates how Sartorius Stedim Biotech SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sartorius Stedim Biotech SA (2005–2024)
The table below shows the annual net assets of Sartorius Stedim Biotech SA from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €4.02 Billion | +50.52% |
| 2023-12-31 | €2.67 Billion | +6.32% |
| 2022-12-31 | €2.51 Billion | +45.06% |
| 2021-12-31 | €1.73 Billion | +16.88% |
| 2020-12-31 | €1.48 Billion | +25.92% |
| 2019-12-31 | €1.18 Billion | +12.71% |
| 2018-12-31 | €1.04 Billion | +18.81% |
| 2017-12-31 | €879.45 Million | +15.18% |
| 2016-12-31 | €763.56 Million | +17.97% |
| 2015-12-31 | €647.22 Million | +20.19% |
| 2014-12-31 | €538.51 Million | +11.76% |
| 2013-12-31 | €481.84 Million | +10.84% |
| 2012-12-31 | €434.72 Million | +9.88% |
| 2011-12-31 | €395.63 Million | +8.37% |
| 2010-12-31 | €365.07 Million | -7.15% |
| 2009-12-31 | €393.20 Million | +5.80% |
| 2008-12-31 | €371.65 Million | +2.45% |
| 2007-12-31 | €362.76 Million | +114.74% |
| 2006-12-31 | €168.93 Million | +13.87% |
| 2005-12-31 | €148.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sartorius Stedim Biotech SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5532.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.50 Billion | 62.61% |
| Common Stock | €19.50 Million | 0.49% |
| Other Comprehensive Income | €1.47 Billion | 36.90% |
| Other Components | €100.00K | 0.00% |
| Total Equity | €3.99 Billion | 100.00% |
Sartorius Stedim Biotech SA Competitors by Market Cap
The table below lists competitors of Sartorius Stedim Biotech SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Reliance Steel & Aluminum Co
NYSE:RS
|
$17.02 Billion |
|
NIO Inc.
BA:NIO
|
$17.03 Billion |
|
ZSCALER INC. DL-,001
XETRA:0ZC
|
$17.04 Billion |
|
Rongsheng Petrochemical Co Ltd
SHE:002493
|
$17.04 Billion |
|
China Shipbuilding Industry Co Ltd
SHG:601989
|
$17.02 Billion |
|
DESTEK FINANS FAKTORING
IS:DSTKF
|
$16.99 Billion |
|
China Overseas Land & Investment Limited
F:CPP
|
$16.96 Billion |
|
Lennox International Inc
NYSE:LII
|
$16.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sartorius Stedim Biotech SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,638,500,000 to 3,986,600,000, a change of 1,348,100,000 (51.1%).
- Net income of 175,100,000 contributed positively to equity growth.
- Dividend payments of 67,100,000 reduced retained earnings.
- Share repurchases of 1,900,000 reduced equity.
- New share issuances of 1,193,600,000 increased equity.
- Other comprehensive income increased equity by 1,242,200,000.
- Other factors decreased equity by 1,193,800,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €175.10 Million | +4.39% |
| Dividends Paid | €67.10 Million | -1.68% |
| Share Repurchases | €1.90 Million | -0.05% |
| Share Issuances | €1.19 Billion | +29.94% |
| Other Comprehensive Income | €1.24 Billion | +31.16% |
| Other Changes | €-1.19 Billion | -29.95% |
| Total Change | €- | 51.09% |
Book Value vs Market Value Analysis
This analysis compares Sartorius Stedim Biotech SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.58x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 130.10x to 4.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €1.45 | €188.70 | x |
| 2006-12-31 | €1.65 | €188.70 | x |
| 2007-12-31 | €3.54 | €188.70 | x |
| 2008-12-31 | €3.61 | €188.70 | x |
| 2009-12-31 | €3.84 | €188.70 | x |
| 2010-12-31 | €3.77 | €188.70 | x |
| 2011-12-31 | €4.27 | €188.70 | x |
| 2012-12-31 | €4.69 | €188.70 | x |
| 2013-12-31 | €5.19 | €188.70 | x |
| 2014-12-31 | €5.78 | €188.70 | x |
| 2015-12-31 | €6.96 | €188.70 | x |
| 2016-12-31 | €8.22 | €188.70 | x |
| 2017-12-31 | €9.46 | €188.70 | x |
| 2018-12-31 | €11.24 | €188.70 | x |
| 2019-12-31 | €12.57 | €188.70 | x |
| 2020-12-31 | €15.84 | €188.70 | x |
| 2021-12-31 | €17.96 | €188.70 | x |
| 2022-12-31 | €26.58 | €188.70 | x |
| 2023-12-31 | €28.63 | €188.70 | x |
| 2024-12-31 | €41.19 | €188.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sartorius Stedim Biotech SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.30%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 2.07x
- Recent ROE (4.39%) is below the historical average (15.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 14.85% | 4.55% | 1.34x | 2.44x | €7.19 Million |
| 2006 | 17.18% | 5.57% | 1.38x | 2.23x | €12.13 Million |
| 2007 | 1.31% | 1.76% | 0.42x | 1.77x | €-31.53 Million |
| 2008 | 3.54% | 3.56% | 0.56x | 1.76x | €-23.87 Million |
| 2009 | 7.40% | 7.25% | 0.60x | 1.70x | €-10.23 Million |
| 2010 | 10.55% | 8.90% | 0.66x | 1.80x | €2.00 Million |
| 2011 | 10.96% | 9.05% | 0.66x | 1.83x | €3.79 Million |
| 2012 | 13.14% | 10.43% | 0.69x | 1.84x | €13.56 Million |
| 2013 | 13.86% | 11.26% | 0.68x | 1.82x | €18.44 Million |
| 2014 | 13.61% | 10.60% | 0.75x | 1.70x | €19.22 Million |
| 2015 | 18.40% | 13.34% | 0.83x | 1.66x | €53.85 Million |
| 2016 | 20.27% | 14.61% | 0.88x | 1.58x | €77.88 Million |
| 2017 | 18.47% | 14.90% | 0.77x | 1.61x | €73.89 Million |
| 2018 | 20.07% | 17.16% | 0.77x | 1.52x | €104.41 Million |
| 2019 | 20.24% | 16.28% | 0.79x | 1.57x | €118.70 Million |
| 2020 | 23.01% | 17.59% | 0.62x | 2.10x | €189.93 Million |
| 2021 | 25.03% | 14.35% | 0.73x | 2.39x | €248.81 Million |
| 2022 | 35.77% | 25.08% | 0.69x | 2.07x | €631.17 Million |
| 2023 | 11.74% | 11.16% | 0.36x | 2.93x | €45.85 Million |
| 2024 | 4.39% | 6.30% | 0.34x | 2.07x | €-223.56 Million |
Industry Comparison
This section compares Sartorius Stedim Biotech SA's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $329,004,321
- Average return on equity (ROE) among peers: -137.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sartorius Stedim Biotech SA (DIM) | €4.07 Billion | 14.85% | 0.93x | $17.02 Billion |
| Crossject (ALCJ) | $3.01 Million | -238.02% | 7.13x | $110.24 Million |
| I.Ceram SA (ALICR) | $4.13 Million | -66.90% | 0.60x | $155.73K |
| Safe Orthopaedics SA (ALSAF) | $1.06 Million | -621.46% | 6.62x | $135.92K |
| Spineway (ALSPW) | $5.12 Million | -1.00% | 0.82x | $6.38 Million |
| Amplitude Surgical SAS (AMPLI) | $118.76 Million | -14.86% | 1.08x | $299.85 Million |
| EssilorLuxottica S. A. (EL) | $2.17 Billion | 16.91% | 0.62x | $116.77 Billion |
| Bonyf NV (MLBON) | $2.68 Million | -38.97% | 0.15x | $2.90 Million |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more